2
项与 COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS) 相关的临床试验Phase 3, Multi-center, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Monovalent Omicron XBB.1.5 Vaccine Administered as a Booster Dose to Adults Who Previously Received COVID-19 Vaccine
The purpose of this study is to assess the immunogenicity and safety of SCB-2023B monovalent Omicron XBB.1.5 vaccine compared to the prototype SCB-2019 vaccine in participants previously vaccinated with 3 doses of inactivated COVID-19 vaccine ≥6 months prior to enrollment.
Phase 3, Multi-center, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of SCB-2023 Vaccine Administered as a Booster Dose to Adults Who Previously Received COVID-19 Vaccine
The purpose of this study is to assess the immunogenicity and safety of SCB-2023 trivalent vaccine compared to the prototype SCB-2019 monovalent vaccine in participants previously vaccinated with 3 doses of inactivated COVID-19 vaccine ≥6 months prior to enrollment.
100 项与 COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS) 相关的临床结果
100 项与 COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS) 相关的转化医学
100 项与 COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS) 相关的专利(医药)
100 项与 COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS) 相关的药物交易